// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Transient Neonatal High Oxygen Exposure Accelerates Adult Cardiac Baseline and Ang Ii-induced Prooxidative and Proinflammatory Responses

Fauve Boudreau - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Angiotensin II

Systematic Review and Meta-analysis of Acute Effects of Alcohol Consumption on Risk of Cardiovascular Events

Harpreet S Chahal - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

20-HETE-mediated Neutrophil Adhesion Impairs Coronary Collateral Growth in Metabolic Syndrome

Amanda Soler - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

ICAM-1

Platelet-derived Growth Factor B: a Novel Determinant of Juxtaglomerular Cell Phenotypic Plasticity?

Edith C Friesema - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Angiology

Calcified vascular disease

follistatin

Ischemia with Mental Stress is Associated with Greater Left Ventricular Dyssynchrony

Ernest V Garcia - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

sestamibi

Matrix Metalloproteinase 2 Knockout Protects from Angiotensin II-induced Vascular Injury

Tlili Barhoumi - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Vasodilation dysfunction

Angiotensin II

Endothelin-1 Overexpression Exaggerates Diabetes-induced Endothelial Dysfunction by Altering Oxidative Stress

Noureddine Idris-Khodja - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Vasodilation dysfunction

Superoxide dismutase

Induction of Human Endothelin-1 Overexpression for 3 Months Causes Blood Pressure Rise and Small Artery Endothelial Dysfunction and Stiffening

Sofiane Ouerd - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Vasodilation dysfunction

Acetylcholine

Nox1 or Nox4 Deletion Prevents Type-1 Diabetes-induced Endothelial Dysfunction

Noureddine Idris-Khodja - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Vasodilation dysfunction

Streptozotocin

Mapping of Chromosome 2 Regions Linked to Vascular Inflammation Using Congenic Rats

Noureddine Idris-Khodja - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

Endothelin-1 Overexpression Preserves Endothelial Function in Mice with Vascular Smooth Muscle Cell-specific Deletion of PPAR-gamma

Noureddine Idris-Khodja - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Angiology

Vasodilation dysfunction

Angiotensin II

Catalyti- Doses of Fructose Improve Glycemic Control but Not Insulin Resistance: A Systematic Review and Meta-Analysis of Controlled Feeding Trials

Jarvis Noronha - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease

Ken Williams - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Patterns of Stroke Transfers and Predictors for Thrombectomy Post-MR CLEAN: a Single Center Experience

Christoph Griessenauer - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Arrhythmia

N/A

Endovascular Thrombectomy and Medical Therapy Versus Medical Therapy Alone in Acute Stroke (EASI): a Randomized Care Trial

Tim E Darsaut - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

N/A

Delayed Phase Blood Pool Assessment of Multiphase-CTA in Acute Stroke Provides Further Information Beyond Non-Contrast CT

Christopher D -Esterre - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

One Threshold Does not Fit All: Hounsfield Unit Thresholds to Segment Clot on NCCT are Patient Specific

Alexis T Wilson - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Rate of Infarct Growth in Acute Ischemic Stroke is Independent of Apparent Diffusion Coefficient Threshold

Saad Khan - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

N/A

Assessing Acute Infarct Growth and Evolution Using Apparent Diffusion Coefficient and Quantitative R2 Imaging

Saad Khan - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Ischemic stroke

N/A

Hospital- Performance on Timely Reperfusion in Stroke and Myocardial Infarction is not Correlated

Deborah A. Levine - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Copyright © 2026. QuantiNova All rights reserved